3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
2
Melanoma
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Adenocarcinoma of the Stomach
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
tesetaxel
×
Clear all
NCT03858972
2021-07-30
CONTESSA 2
Odonate Therapeutics, Inc.
Phase 2
Terminated
152 enrolled
NCT03952325
2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2
Terminated
294 enrolled